🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

95 results for “Base” Clear

  1. The min-102 placebo is supplied as an oral suspension with similar appearance to min-102 drug product. min-102 placebo oral suspension is packaged in an amber glass bottle with filled volume based on the required clinical dose

    Minoryx Therapeutics S.L.

    Rett Syndrome

    phase 2 small molecule active

    1 trial

  2. Theory-based counseling program

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 other completed

    1 trial

  3. Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.

    The George Institute

    Breast cancer

    phase 2 other active

    1 trial

  4. Virtual Reality based distraction

    BRIGHT MINDS BIOSCIENCES INC.

    Pain

    phase 2 other completed

    1 trial

  5. employment-based reinforcement

    BRIGHT MINDS BIOSCIENCES INC.

    Opiate Dependence

    phase 2 other completed

    1 trial

  6. empowerment theory-based small group discussion

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infection

    phase 2 other completed

    1 trial

  7. lurbinectedin, JEMPERLI 500 mg concentrate for solution for infusion

    The George Institute

    Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy

    phase 2 small molecule active

    1 trial

  8. telephone based skills training intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 other completed

    1 trial

  9. A Phase I study to evaluate the safety and dosimetry of 68Ga-OncoACP3 in patients with prostate cancer

    Philogen S.p.A.

    Patients with prostate cancer with: -suspected metastasis who are candidates for initial definitive therapy -suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) -metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

    phase 1 other active

    1 trial

  10. A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.

    Philogen S.p.A.

    Patients with prostate cancer with: - suspected metastasis who are candidates for initial definitive therapy - suspected recurrence based on elevated serum prostate-specific antigen (PSA) level (i.e., a progressive and confirmed serum PSA level > 0.2 ng/mL) - metastatic disease who might be candidates for treatment with 177Lu-labelled PSMA ligands

    phase 1 other active

    1 trial

  11. A randomised, open-label, parallel group study to compare the pharmacokinetics and pharmacodynamics of NEODIDRO® 0.266 mg vs DIBASE® 25,000 IU oral doses in male and female patients.

    Verona Pharma Ireland Limited

    Patients with low Vitamin D plasma level

    phase 1 other active

    1 trial

  12. ATA3219

    Evidence Based Cataract Study Group

    Lupus Nephritis

    phase 1 small molecule terminated

    1 trial

  13. ATA3219

    Evidence Based Cataract Study Group

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule terminated

    1 trial

  14. An exploratory study to investigate the impact on the viral reservoir of adding a broadly neutralizing antibody with or without an attachment inhibitor to an integrase inhibitor-based antiretroviral therapy regimen in adults living with HIV (ENTRANCE)

    ViiV Healthcare Pty Ltd

    HIV Infections

    phase 1 other active

    1 trial

  15. An open label, phase 1 study to evaluate the safety, feasibility and immunogenicity of an allogeneic, cell-based vaccine (VIDIDENCEL) in high grade serous ovarian cancer patients after primary treatment (ALISON)

    Disc Medicine

    High grade serous ovarian cancer

    phase 1 other active

    1 trial

  16. An open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC), in adult patients with newly diagnosed glioblastoma (GBM).

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 1 other active

    1 trial

  17. Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after platinum-based therapy.

    Alphapharm Pty Ltd

    Small cell lung cancer

    phase 1 other active

    1 trial

  18. FVH1 - a DNA-based influenza vaccine

    INOVIO PHARMACEUTICALS, INC.

    Influenza, Human

    phase 1 mab completed

    1 trial

  19. Investigator-Selected Standard PD-1/PD-L1 Inhibitor-Based Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumors

    phase 1 small molecule active

    1 trial

  20. KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

    Boehringer Ingelheim

    G12D/G12V Pancreatic Ductal Adenocarcinoma

    phase 1 other active

    1 trial

  21. M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

    Merck Sharp and Dohme

    Advanced solid tumors and colorectal cancer

    phase 1 other active

    1 trial

  22. Novel Supplement Based Therapy

    Atrium Therapeutics

    Small Intestinal Bacterial Overgrowth

    phase 1 other terminated

    1 trial

  23. Oxycodone IN

    BRIGHT MINDS BIOSCIENCES INC.

    Physiologically Based Pharmacokinetic

    phase 1 small molecule completed

    1 trial

  24. Pharmacy-based methadone administration and dispensing

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources